Literature DB >> 10392822

Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes?

S Bieri1, M Rouzaud, R Miralbell.   

Abstract

PURPOSE: To evaluate the influence of different shielding conditions and field geometry on the scatter dose to the remaining testicle during postoperative radiotherapy (RT) in seminoma.
MATERIALS AND METHODS: Testicular dose measurements were made with LiF thermoluminescent dosimeters (TLD) in 29 patients with stage I and IIA seminoma. The target volume consisted of para-aortic (PA) and para-aortic and homolateral iliac (PAI) lymph nodes in 14 and 15 patients, respectively. All patients had a scrotal shield as well as an additional block extending 7 cm inferiorly from the caudal field edge to shield the testicle from external scatter and collimator leakage. Doses with and without testicular blocks were measured for all patients. In seven patients treated exclusively to the PA region the gonadal dose was assessed according to four different shielding conditions: without any protection, with a gonadal shield alone, with the addition of an inferior field border block to the gonadal shield, and with the field border block alone.
RESULTS: For patients treated with PAI fields the mean testicular doses per fraction were 3.89 cGy (S.D. +/- 1.44) and 1.48 cGy (S.D. +/- 0.51) without and with gonadal shielding, respectively (P-value < 0.001); the corresponding values for PA fields were 1.86 cGy (S.D. +/- 0.86) and 0.65 cGy (S.D. +/- 0.35). For the patients treated to the PA region and assessed according to the four different shielding conditions, the additional external block to the testicular shield did not reduce significantly the measured dose on the testis.
CONCLUSIONS: These results suggest a benefit of gonadal shielding even in seminoma patients undergoing radiotherapy limited to the para-aortic region.

Entities:  

Mesh:

Year:  1999        PMID: 10392822     DOI: 10.1016/s0167-8140(99)00023-7

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma.

Authors:  Charles B Simone; Kevin Kramer; William P O'Meara; Justin E Bekelman; Arnaud Belard; James McDonough; John O'Connell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-13       Impact factor: 7.038

2.  Adaptive planning using megavoltage fan-beam CT for radiation therapy with testicular shielding.

Authors:  Poonam Yadav; Kevin Kozak; Ranjini Tolakanahalli; V Ramasubramanian; Bhudatt R Paliwal; James S Welsh; Yi Rong
Journal:  Med Dosim       Date:  2011-09-16       Impact factor: 1.482

Review 3.  Fertility preservation strategies for male patients with cancer.

Authors:  Darren J Katz; Thomas F Kolon; Darren R Feldman; John P Mulhall
Journal:  Nat Rev Urol       Date:  2013-07-09       Impact factor: 14.432

4.  Testicular Dose During Prophylaxis of Heterotopic Ossification with Radiation Therapy.

Authors:  Waleed F Mourad; John K Ma; Satyaseelan Packianathan; Weisi Yan; Sherif G Shaaban; Edward M Marchan; Lamiaa E Abdallah; Rei He; Paul N Mobit; Chunli Claus Yang; Srinivasan Vijayakumar
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

5.  Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma.

Authors:  Karen E Hoffman; Ming-Hui Chen; Rinaa S Punglia; Clair J Beard; Anthony V D'Amico
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

6.  Stage I testicular seminoma: a SEER analysis of contemporary adjuvant radiotherapy trends.

Authors:  Alan E Thong; Daphne Y Lichtensztajn; Leanne Almario; Alexandre Ingels; Scarlett Lin Gomez; Mark L Gonzalgo
Journal:  J Urol       Date:  2013-04-06       Impact factor: 7.450

Review 7.  Contemporary management of stage I and II seminoma.

Authors:  Peter Chung; Padraig Warde
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

8.  Testicular shield for para-aortic radiotherapy and estimation of gonad doses.

Authors:  R Ravichandran; J P Binukumar; S Kannadhasan; M H Shariff; Kamal El Ghamrawy
Journal:  J Med Phys       Date:  2008-10

Review 9.  Fatherhood and Sperm DNA Damage in Testicular Cancer Patients.

Authors:  Donatella Paoli; Francesco Pallotti; Andrea Lenzi; Francesco Lombardo
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-13       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.